Actelion, a subsidiary of Johnson & Johnson, received preliminary approval from a U.S. District Court for a $65 million settlement in a certified antitrust class action. The case accuses Actelion of blocking generic manufacturers from obtaining samples of its pulmonary arterial hypertension drug, Tracleer, thereby delaying the launch of a cheaper generic version for nearly four years after the drug’s patents expired.
The settlement resolves claims that Actelion engaged in a scheme to prevent generic manufacturers from accessing Tracleer samples, a requirement for FDA bioequivalence testing. The class of plaintiffs includes government employees and other payors who allegedly overcharged for Tracleer between December 2015 and September 2024. The court’s decision was reached less than two weeks before a 25‑day jury trial scheduled to begin on March 2, 2026, and the settlement clears a legal hurdle that could have continued to impact pricing and reimbursement for the drug.
Actelion was acquired by Johnson & Johnson in 2017 for approximately $30 billion. Tracleer has been a highly profitable product for the company, generating billions in sales. The $65 million settlement represents a legal expense for J&J, but it is small relative to the company’s overall size and does not materially alter its financial outlook. However, the settlement removes a potential source of reputational risk and eliminates the uncertainty that a trial could have introduced.
The settlement is material to Johnson & Johnson because it involves a substantial legal expense for one of its subsidiaries and addresses a long‑running antitrust dispute that could have affected the company’s reputation and financial performance. The approval of the settlement is a concrete event that occurred on March 13, 2026, and has not been previously reported in J&J’s own news releases.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.